Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathicpulmonary fibrosis: a preliminary study
Turkish Journal of Biology · 20.12.2024 · 48 (6) · 379-389
DOI: 10.55730/1300-0152.2713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Biology, online erschienen am 20.12.2024. Verfasst von Sevil Köse und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Akdeniz University, Antalya, Turkiye. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aim: There is no specific pharmacological treatment regimen for idiopathic pulmonary fibrosis (IPF). Therefore, new anti-inflammatory therapeutic strategies are needed. Cannabinoids (CBs) that are known for their inflammation-modulating and anti-fibrotic effects may be potential medication candidates for the treatment of IPF. Our aim is to evaluate the inflammation-modulating and anti-fibrotic effects of CB receptor (CBR) agonists and antagonists in lipopolysaccharide (LPS) stimulated human lung healthy fibroblast, epithelial cells, IPF fibroblast cells and monocytes.Materials and methods: We detected CBRs in the human lung healthy (LL24) and IPF fibroblast cells (LL29), epithelial cells (A549) and monocytes (THP-1) by flow cytometry (FC). We determined TGF-β1, IL-8 and TNF-α inflammatory cytokines in the LL24, LL29, A549 and THP-1 cell culture supernatants on day 1 and 5 by ELISA. We evaluated the cell viability in LL24, LL29 and A549 cells on days 1, 3 and 5 spectrophotometrically. We detected collagen Type I (ColI) production in the LL24 and LL29 cell culture supernatants on days 1, 3 and 5 by ELISA.
Results
LL24, LL29, A549 and THP-1 cells presented CB1 (CB1R) and CB2 (CB2R) receptors. CB1R and CB2R agonists WIN55,212-2 and JWH015 inhibited fibroblastic and epithelial cell proliferation on day 5. TGF-β1 and TNF-α release increased, while IL-8 release decreased in LL24, LL29, A549 and THP-1 cells in response to administration of WIN55,212-2 and JWH015 at 10-2 mM concentration. CB1R and CB2R antagonists AM251 and AM630, respectively, did not block agonistic responses, suggesting a non-classical CBR mediated pathway. CB2R agonist JWH015 decreased ColI expression from IPF lung fibroblasts LL29 on day 3.
Conclusion
These results suggest that CB signaling plays a regulatory role in the progress of pulmonary inflammation and fibrosis and via CBR activation that may offer a potential pharmacological tool for developing antifibrosis therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Akdeniz University, Antalya, Turkiye.
- Department of Medical Biology, Faculty of Medicine, Atılım University, Ankara, Turkiye.
- METU MEMS Center, Ankara, Turkiye.
- Department of Pathology, Medical School, Atılım University, Ankara, Turkiye.
- Department of Pulmonary Diseases, Medical School, Atılım University, Ankara, Turkiye.
- Department of Histology and Embryology, Faculty of Medicine, Hacettepe University, Ankara, Turkiye.
ORCID-Profile: Sevil Köse, Selin Önen, Merve Gizer, Esin Boduroğlu, Uğur Gönüllü, Petek Korkusuz
Zitieren
APA
Köse, S., Önen, S., Gizer, M., Boduroğlu, E., Gönüllü, U., & Korkusuz, P. (2024). Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathicpulmonary fibrosis: a preliminary study. Turkish Journal of Biology, 48(6), 379-389. https://doi.org/10.55730/1300-0152.2713
Vancouver
Köse S, Önen S, Gizer M, Boduroğlu E, Gönüllü U, Korkusuz P. Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathicpulmonary fibrosis: a preliminary study. Turkish Journal of Biology. 2024;48(6):379-389. doi:10.55730/1300-0152.2713
BibTeX
@article{Kse2024,
author = {Köse, Sevil and Önen, Selin and Gizer, Merve and Boduroğlu, Esin and Gönüllü, Uğur and Korkusuz, Petek},
title = {Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathicpulmonary fibrosis: a preliminary study},
journal = {Turkish Journal of Biology},
year = {2024},
volume = {48},
number = {6},
pages = {379--389},
doi = {10.55730/1300-0152.2713}
}
EUVIMED